Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

2010 FDA drug approvals

Nature Reviews Drug Discovery volume 10, pages 82–85 (2011)Cite this article

Subjects

An Erratum to this article was published on 08 February 2011

This article has been updated

The US Food and Drug Administration approved slightly fewer new drugs than in recent years, and the industry's focus on specialty-care products continued to shine through.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: FDA drug approvals since 1996.

Change history

  • 08 February 2011

    The company names of Cerexa and Sunovion were transposed in Table 1 and have been corrected online.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mullard, A. 2010 FDA drug approvals. Nat Rev Drug Discov 10, 82–85 (2011). https://doi.org/10.1038/nrd3370

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3370

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research